Protalix Announces NDA Submission Update for taliglucerase alfa for the Treatment of Gaucher Disease

2 February, 2010

Protalix BioTherapeutics announced today that, in connection with the New Drug Application (NDA) filed by the Company in December 2009 for taliglucerase alfa for the treatment of Gaucher disease, the U.S. Food and Drug Administration (FDA) has requested additional data regarding the Chemistry, Manufacturing and Controls (CMC) section of the NDA